Taiho’s Lytgobi Faces Heavy Competition, But Sets Efficacy Bar For Now
Executive Summary
The FGFR inhibitor beats prior entrants on efficacy in cholangiocarcinoma, although Relay presented data at ESMO for its investigational RLY-4008 showing especially high efficacy and tolerability.